AB Science fait le point sur le programme clinique du masitinib
05 août 2019 01h31 HE
|
AB Science
Paris, 5 août 2019, 7h30 Point sur le programme clinique du masitinib AB Science SA (NYSE Euronext - FR0010557264 - AB) fait le point sur le programme clinique du masitinib. Les points...
AB Science annonce aujourd’hui les résultats de son étude de phase 3 évaluant le masitinib chez des patients atteints de mélanome non opérable ou métastatique de stade 3 ou stade 4
02 août 2019 11h44 HE
|
AB Science
Paris, 2 août 2019, 17h30 AB Science annonce de nouveaux résultats cliniques en oncologie :L’activité du masitinib a été démontrée dans le mélanome métastatiqueprésentant une mutation du domaine...
AB Science today reports the analysis for its phase 3 trial evaluating masitinib in patients with non-resectable or metastatic stage 3 or stage 4 melanoma
02 août 2019 11h44 HE
|
AB Science
Paris, August 2, 2019, 5.30pm AB Science announces new clinical results in oncology: Masitinib showed activity in metastatic melanoma bearingthe juxta-membrane mutation of c-Kit AB...
Organovo Affirms Key Clinical Development Goals; Company Reports Fiscal Second-Quarter 2019 Results
08 nov. 2018 16h05 HE
|
Organovo, Inc.
Pre-Investigational New Drug (“IND”) meeting with the FDA expected to be held in calendar 2019Second orphan designation anticipated in first half of calendar 2019Submit first IND in calendar 2020 ...
Achillion Announces ACH-4471 Receives Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of C3 Glomerulopathy
26 févr. 2018 06h05 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a biopharmaceutical company focused on advancing small molecule factor D inhibitors to modulate the...
Protalix BioTherapeutics to Hold Full-Year 2016 Financial Results and Corporate Update Conference Call on March 16, 2017
09 mars 2017 07h30 HE
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, March 09, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...
XOMA Announces Significant Step Toward Initiating Pediatric Phase 2 Clinical Study for XOMA 358 in Children with Congenital Hyperinsulinism
19 oct. 2016 09h00 HE
|
XOMA Ltd.
BERKELEY, Calif., Oct. 19, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today the United Kingdom’s...
Achillion Reports Second Quarter 2016 Financial Results
04 août 2016 16h05 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn. , Aug. 04, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and six months ended June 30, 2016. For the second...
Achillion Announces Upcoming Oral Presentation at the 57th Annual Meeting of the American Society of Hematology and Nomination of ACH-4471, a Novel Small Molecule Factor D Inhibitor, for Clinical Development
05 déc. 2015 17h00 HE
|
Achillion Pharmaceuticals, Inc.
- Presentation will highlight ACH-4471, a highly potent, specific, and orally-administered factor D inhibitor, and preclinical data on its ability to block hemolysis of paroxysmal nocturnal...
Achillion Reports Third Quarter And Nine Month 2015 Financial Results
05 nov. 2015 17h51 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and nine months ended September 30, 2015. For the...